We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Telmisartanis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Telmisartan studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2008–2018 with a typical study size of 20,332 participants.
Based on 7 studies · 1 meta-analysis · 5 RCTs · 77,552 total participants
Confidence
HighBy outcome
Telmisartan has an evidence score of 4.3/10 — emerging evidence based on 7 indexed studies, including 1 meta-analysis. An angiotensin-receptor blocker (Micardis) that is unusual among RAS drugs for also being a partial PPARγ agonist — the receptor that glitazone diabetes drugs target. That dual action gives it a metabolic edge: across head-to-head RCTs and a meta-analysis it improves insulin sensitivity, glucose, and lipids more than other ARBs, which is why it features in geroscience discussions. But it is an approved blood-pressure drug whose proven outcomes are cardiovascular, not a demonstrated lifespan/healthspan benefit — and its own pivotal trials show no superiority over ramipril (ONTARGET) and no recurrent-stroke reduction (PRoFESS). A prescription drug, not a supplement. Representative study: PMID 29557807.
The commonly studied dose of Telmisartan is Approved antihypertensive dosing is 20–80 mg once daily; the metabolic/PPARγ effects are most evident at the higher 80 mg (and study) doses, under a clinician. Not an approved metabolic or longevity regimen; blood pressure, kidney function, and potassium should be monitored.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
Verapamil
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Telmisartan (Micardis) — angiotensin-receptor blocker (ARB) + partial PPARγ agonist
An angiotensin-receptor blocker (Micardis) that is unusual among RAS drugs for also being a partial PPARγ agonist — the receptor that glitazone diabetes drugs target. That dual action gives it a metabolic edge: across head-to-head RCTs and a meta-analysis it improves insulin sensitivity, glucose, and lipids more than other ARBs, which is why it features in geroscience discussions. But it is an approved blood-pressure drug whose proven outcomes are cardiovascular, not a demonstrated lifespan/healthspan benefit — and its own pivotal trials show no superiority over ramipril (ONTARGET) and no recurrent-stroke reduction (PRoFESS). A prescription drug, not a supplement.
Telmisartan is the one ARB that is also a partial PPARγ agonist — head-to-head RCTs and a meta-analysis show it improves insulin sensitivity, glucose, and lipids more than other ARBs, and mechanistic RCTs confirm it engages PPARγ target genes in humans, giving it a real metabolic/geroscience angle. But its proven outcomes are cardiovascular (ONTARGET: non-inferior to ramipril), the metabolic endpoints are surrogate markers not lifespan, ONTARGET showed no superiority and the combination arm increased renal harm, and PRoFESS was a clean negative stroke trial — so the metabolic-longevity use stays emerging.
Telmisartan is an angiotensin II type-1 (AT1) receptor blocker (ARB) marketed as Micardis — a long-acting, once-daily antihypertensive.
What sets it apart from the rest of its class, and from the other renin-angiotensin (RAS) drugs in this collection (losartan, captopril), is a second pharmacology: telmisartan is a partial agonist of peroxisome proliferator-activated receptor-gamma (PPARγ), the nuclear receptor that the glitazone (thiazolidinedione) diabetes drugs activate.
As a *selective* PPARγ modulator it engages the receptor enough to favorably shift glucose and lipid metabolism without the full-agonist downsides of fluid retention and weight gain (Kurtz 2008). That dual AT1-blockade-plus-PPARγ profile is the source of its metabolic and geroscience interest.
The human evidence for the metabolic angle is real but modest: head-to-head RCTs against other ARBs show telmisartan improves insulin sensitivity, fasting glucose, and lipids more than comparators, a meta-analysis pooling those trials concludes telmisartan improves insulin resistance relative to other ARBs (Wang 2018), and mechanistic RCTs in metabolic-syndrome patients show high-dose telmisartan induces monocytic PPARγ target genes (Bähr 2011) — direct in-human confirmation that the PPARγ pathway is engaged.
The honest distinction this collection insists on: the PPARγ/metabolic-syndrome story is mechanistically genuine and is discussed in the geroscience literature (PPARγ and RAS modulation are both candidate metabolic-aging levers), but it has NOT been shown to extend lifespan or healthspan — the endpoints in the human trials are surrogate metabolic markers, not aging or mortality.
On the cardiovascular side the evidence is solid: ONTARGET (Yusuf 2008) established telmisartan as non-inferior to the gold-standard ACE inhibitor ramipril for the composite of cardiovascular death, MI, stroke, and heart-failure hospitalization in high-vascular-risk patients — but it showed no *superiority*, and the combination arm (ARB + ACE inhibitor together) caused MORE harm, with worse renal outcomes including more dialysis/creatinine-doubling and hypotension.
TRANSCEND (Yusuf 2008) extended telmisartan to patients intolerant of ACE inhibitors.
The best counter-evidence is PRoFESS (Yusuf 2008): in 20,000+ patients started on telmisartan soon after an ischemic stroke, it did NOT significantly reduce recurrent stroke — a large, clean negative trial that caps the cerebrovascular claim.
Telmisartan is generally well tolerated (ARB class — less cough than ACE inhibitors); class effects are dizziness/hypotension, hyperkalemia, and a contraindication in pregnancy.
It is a prescription cardiovascular drug; using it off-label for metabolic/longevity ends is increasingly discussed, but the longevity benefit specifically is unproven.
The score reflects a genuinely distinctive, in-human-confirmed PPARγ/metabolic mechanism plus solid cardiovascular outcome data, against unproven human longevity, no superiority over ramipril, and a clear negative stroke trial.
Telmisartan blocks the angiotensin II type-1 (AT1) receptor, lowering angiotensin II signaling — the renin-angiotensin axis that, beyond blood pressure, drives inflammation, oxidative stress, fibrosis, and senescence.
Uniquely among ARBs, telmisartan partially activates PPARγ — the nuclear receptor glitazone diabetes drugs target — as a selective modulator, improving glucose/lipid metabolism without the full-agonist fluid retention and weight gain (Kurtz 2008).
How Telmisartan works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Approved antihypertensive dosing is 20–80 mg once daily; the metabolic/PPARγ effects are most evident at the higher 80 mg (and study) doses, under a clinician. Not an approved metabolic or longevity regimen; blood pressure, kidney function, and potassium should be monitored.
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral tablet (telmisartan) | Recommended |
| 💊Losartan / candesartan / valsartan (other ARBs — but without the PPARγ metabolic profile) | Alternative |
Telmisartan is the ARB with the strongest PPARγ partial-agonist activity; the cardiovascular class effects are shared, but the metabolic edge is telmisartan-specific.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: Once daily; monitor blood pressure, kidney function, and potassium. Antihypertensive effect builds over ~4 weeks; metabolic effects are dose-dependent.
Dose-response data unavailable. The current published research for Telmisartan does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
ONTARGET showed telmisartan non-inferior to ramipril for cardiovascular death, MI, stroke, and heart-failure hospitalization in high-risk patients (human RCT).
Via partial PPARγ agonism, telmisartan improves insulin resistance, glucose, and lipids more than other ARBs — surrogate metabolic markers, not a longevity outcome.
In 20,000+ patients started on telmisartan soon after ischemic stroke, it did NOT significantly reduce recurrent stroke — a large negative trial.
Dizziness and hypotension, possible high potassium; contraindicated in pregnancy. The ARB+ACE combination increases renal harm — do not combine.
Contraindicated — ARBs cause fetal renal and developmental harm.
Monitor kidney function and potassium closely; never add an ACE inhibitor.
Caution — hypotension risk; correct dehydration first and start low.
Combining an ARB with an ACE inhibitor increased renal failure, hyperkalemia, and hypotension in ONTARGET without added benefit — avoid.
Additive hyperkalemia risk — can be dangerous.
Reduce ARB effect and can worsen renal function (the 'triple whammy' with diuretics).
Tip: Most likely with dehydration or alongside diuretics; start low and rise slowly.
Tip: Monitor potassium; avoid potassium supplements/salt substitutes, especially in renal impairment.
Tip: Much rarer than with ACE inhibitors; stop immediately and seek care.
The best time to take Telmisartan is in the morning. It can be taken on an empty stomach. Long-acting; taken once daily, with or without food.
Telmisartan should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are dizziness / hypotension, hyperkalemia, angioedema. Use caution if any of these apply to you: Pregnancy (fetal harm); Bilateral renal artery stenosis; Hyperkalemia.
A decades-old non-dihydropyridine calcium-channel blocker for hypertension, angina, and arrhythmia, being repurposed to PRESERVE pancreatic beta-cell function in new-onset type-1 diabetes. Two randomized trials (adults — Nature Medicine 2018; children/adolescents — JAMA 2023, CLVer) show it partially preserves C-peptide. The benefit is partial and adjunctive — not a cure, and it wanes after stopping. A prescription drug, not a supplement.
Via PPARγ engagement, telmisartan improves insulin sensitivity and lipids more than other ARBs in head-to-head trials, and induces PPARγ target genes (CD36/CD163) in human monocytes (Bähr 2011).
ARBs raise lithium levels and toxicity risk.